UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

European journal of pharmacology, 2014-04, Vol.728, p.31-38

2014

Volltextzugriff (PDF)

Neuropeptide Y (NPY) Y4 Receptor Selective Agonists Based on NPY(32−36): Development of an Anorectic Y4 Receptor Selective Agonist with Picomolar Affinity

Journal of medicinal chemistry, 2006-04, Vol.49 (8), p.2661-2665

2006

Volltextzugriff (PDF)

Identification of Potent and Selective Neuropeptide Y Y1 Receptor Agonists with Orexigenic Activity in Vivo

Molecular pharmacology, 2001-09, Vol.60 (3), p.534

2001

Volltextzugriff (PDF)

Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists

Bioorganic & medicinal chemistry letters, 2009-12, Vol.19 (23), p.6801-6805

2009

Volltextzugriff (PDF)

Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y1, Y2, Y4 and Y5 receptor subtypes

Regulatory peptides, 2002-04, Vol.105 (1), p.65-73

2002

Volltextzugriff (PDF)

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor anatgonists

Bioorganic & medicinal chemistry letters, 2009-11, Vol.19 (21), p.6018-6022

2009

Volltextzugriff (PDF)

Activation of the NPY Y5 receptor regulates both feeding and energy expenditure

American journal of physiology. Regulatory, integrative and comparative physiology, 1999-11, Vol.277 (5), p.1428-R1434

1999

Volltextzugriff (PDF)

[D-Trp34] neuropeptide Y is a potent and selective neuropeptide Y Y5 receptor agonist with dramatic effects on food intake

Peptides (New York, N.Y. : 1980), 2000-03, Vol.21 (3), p.393-399

2000

Volltextzugriff (PDF)

Highly Selective and Potent Neuropeptide Y (NPY) Y1 Receptor Antagonists Based on [Pro30, Tyr32, Leu34]NPY(28-36)-NH2 (BW1911U90)

Journal of medicinal chemistry, 2001-05, Vol.44 (10), p.1479-1482

2001

Volltextzugriff (PDF)

GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists

European journal of pharmacology, 1998-05, Vol.349 (1), p.97-105

1998

Volltextzugriff (PDF)

Pharmacological characterization of the cloned neuropeptide Y y6 receptor

European journal of pharmacology, 2000-04, Vol.395 (2), p.87-93

2000

Volltextzugriff (PDF)

Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists

Bioorganic & medicinal chemistry letters, 2016-02, Vol.26 (4), p.1348-1354

2016

Volltextzugriff (PDF)

Discovery of aminoquinazoline derivatives as human A2A adenosine receptor antagonists

Bioorganic & medicinal chemistry letters, 2016-02, Vol.26 (4), p.1348-1354

2016

Volltextzugriff (PDF)

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia

Bioorganic & medicinal chemistry letters, 2012-01, Vol.22 (1), p.235-239

2012

Volltextzugriff (PDF)

Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists

Bioorganic & medicinal chemistry letters, 2015-08, Vol.25 (15), p.2958-2962

2015

Volltextzugriff (PDF)

Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2015-08, Vol.25 (15), p.2958-2962

2015

Volltextzugriff (PDF)

Discovery of aminoquinazoline derivatives as human A sub(2A) adenosine receptor antagonists

Bioorganic & medicinal chemistry letters, 2016-02, Vol.26 (4), p.1348-1354

2016

Volltextzugriff (PDF)

Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compound

Bioorganic & medicinal chemistry letters, 2012-02, Vol.22 (3), p.1335-1339

2012

Volltextzugriff (PDF)

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

European journal of pharmacology, 2014-05, Vol.730, p.157-163

2014

Volltextzugriff (PDF)

The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia

Bioorganic & medicinal chemistry letters, 2012-01, Vol.22 (2), p.1019-1022

2012

Volltextzugriff (PDF)

The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (7), p.2585-2589

2012

Volltextzugriff (PDF)

Effects of the selective adenosine A sub(2A) receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

European journal of pharmacology, 2014-04, Vol.728, p.31-38

2014

Volltextzugriff (PDF)

Discovery and SAR of cyclic isothioureas as novel NPY Y 1 receptor antagonists

Bioorganic & medicinal chemistry letters, 2009-12, Vol.19 (23), p.6801-6805

2009

Volltextzugriff (PDF)

Neuropeptide Y (NPY) Y 4 Receptor Selective Agonists Based on NPY(32−36): Development of an Anorectic Y 4 Receptor Selective Agonist with Picomolar Affinity

Journal of medicinal chemistry, 2006-04, Vol.49 (8), p.2661-2665

2006

Volltextzugriff (PDF)

Corrigendum to “Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists” [Bioorg. Med. Chem. Lett. 19 (2009) 6801]

Bioorganic & medicinal chemistry letters, 2010-03, Vol.20 (5), p.1800

2010

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(48)
Dissertationen
(1)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

Neuropeptide Y (NPY) Y4 Receptor Selective Agonists Based on NPY(32−36): Development of an Anorectic Y4 Receptor Selective Agonist with Picomolar Affinity

Identification of Potent and Selective Neuropeptide Y Y1 Receptor Agonists with Orexigenic Activity in Vivo

Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists

Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y1, Y2, Y4 and Y5 receptor subtypes

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor anatgonists

Activation of the NPY Y5 receptor regulates both feeding and energy expenditure

[D-Trp34] neuropeptide Y is a potent and selective neuropeptide Y Y5 receptor agonist with dramatic effects on food intake

Highly Selective and Potent Neuropeptide Y (NPY) Y1 Receptor Antagonists Based on [Pro30, Tyr32, Leu34]NPY(28-36)-NH2 (BW1911U90)

GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists

Pharmacological characterization of the cloned neuropeptide Y y6 receptor

Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists

Discovery of aminoquinazoline derivatives as human A2A adenosine receptor antagonists

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia

Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists

Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists

Discovery of aminoquinazoline derivatives as human A sub(2A) adenosine receptor antagonists

Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compound

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia

The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia

Effects of the selective adenosine A sub(2A) receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

Discovery and SAR of cyclic isothioureas as novel NPY Y 1 receptor antagonists

Neuropeptide Y (NPY) Y 4 Receptor Selective Agonists Based on NPY(32−36): Development of an Anorectic Y 4 Receptor Selective Agonist with Picomolar Affinity

Corrigendum to “Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists” [Bioorg. Med. Chem. Lett. 19 (2009) 6801]

Suchergebnisse filtern